

RESEARCH OUTPUTS / RÉSULTATS DE RECHERCHE

Transferability of ETP-based APC resistance assay on the ST Genesia system

Morimont, Laure; Didembourg, Marie; Carlo, Audrey ; DOGNE, Jean-Michel; Douxfils, Jonathan

Published in:
ECTH 2021 - Abstract Book, 14-15 October 2021

Publication date:
2021

[Link to publication](#)

Citation for pulished version (HARVARD):
Morimont, L, Didembourg, M, Carlo, A, DOGNE, J-M & Douxfils, J 2021, Transferability of ETP-based APC resistance assay on the ST Genesia system. in *ECTH 2021 - Abstract Book, 14-15 October 2021.*, P056, pp. 87, ECTH 2021, Gand, Belgium, 14/10/21.

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal ?

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Transferability of ETP-based APC resistance assay on the ST Genesis system



L. Morimont^{1,2}, M. Didembourg², A. Carlo³, J-M. Dogné², J. Douxfils^{1,2}

¹Qualiblood sa, Namur, Belgium; ²University of Namur, Faculty of Medicine, Department of Pharmacy, Namur Research Institute for Life Sciences (NARILIS), Namur Thrombosis and Hemostasis Center (NTHC), Namur, Belgium; ³ Diagnostica Stago, Asnières-sur Seine, France.

Laure.morimont@qualiblood.eu

BACKGROUND

- Regulatory bodies recommend assessing the ETP-based APC resistance assay during the development of steroid contraceptives.
- In 2019, this assay was validated on the Calibrated Automated Thrombogram using commercially available reagents to ensure batch-to-batch traceability, and reproducibility of the method over time.

AIMS

To implement the ETP-based APC resistance assay on the automated ST Genesis system using reagent STG-ThromboScreen -TM (TS -TM) with exogenous APC added.

METHODS

- Determination of APC concentration leading to 90%±2.5% of ETP inhibition of a healthy pooled plasma, using 2 different batches of TS -TM.
- Intra- (N=5) and inter-run (N=10) reproducibility of ETP inhibition assessed on 3 lyophilized samples.
- Reference ranges defined based on 56 plasma samples.
- Sensitivity assessed on 36 females using combined oral contraceptives (COCs).

RESULTS

- [APC]_{mU/mL} defined at 652 mU/mL [IC95%: 534-805 mU/mL] on both batches of TS - TM (**Figure 1**).
- ETP inhibition SD <2.0% for intra-run and <3.5% for inter-run reproducibility (**Table 1**).
- Mean ETP inhibition % [IC95] over 56 samples equaled 89.5% [87.3%-91.6%] (**Figure 2**).
- Significantly lesser response to APC of women using COC compared to healthy individuals (**Figure 2**).

SUMMARY/CONCLUSION

This study is the first reporting the transferability of the ETP-based APC resistance assay on the ST Genesis system. Data revealed excellent precision (within- and between-run reproducibility) and provided an appropriate sensitivity depending on the hormonal status of women. Confirmation of promising results on thrombogenicity identification for all COC users is still needed before this test can be commercially available.




Figure 1: Inhibition percentages of ETP of a healthy pooled plasma (HPP) at various concentrations of APC (mU/mL), using two batches of TS -TM. The blue continuous line represents the mean non-linear regression obtained with both batches of TS -TM. The horizontal grey dotted lines represent the maximal tolerated inhibition percentage of HPP, corresponding to 90% ±2.5%. The red vertical lines represent the APC concentration [IC95] leading to 90% of inhibition of the ETP and corresponds to 652 mU/mL [534-805 mU/mL].

Tested plasma	ETP inhibition reproducibility	
	Intra-run (N=5) Mean ± SD	Inter-run (N=10) Mean ± SD
STG-RefPlasma TS	73.5% ± 1.0%	74.5% ± 3.5%
STG-QualiTest Norm TS	38.5% ± 2.0%	37.7% ± 3.5%
STG-QualiTest High TS	8.7% ± 1.7%	10.1% ± 1.4%

Table 1: Intra-run and inter-run reproducibility of ETP inhibition of the commercial reference plasma and two quality controls. Intra-run reproducibility was based on 5 measurements of each tested plasma and the inter-run reproducibility was based on 10 runs measuring each tested plasma. Results are expressed as mean inhibition % ± standard deviation (SD)




Figure 2: Inhibition % of ETP of individuals from each subgroup, i.e., healthy individuals (N=56), women using COC containing: - ethinylestradiol (EE) + levonorgestrel (LNG) (N=18); - EE + desogestrel (DSG)/gestodene (GSD) (N=12); - EE + drospirenone (DRSP)/cyproterone acetate (CPA)/dienogest (DNG) (N=6). Individuals values and mean ETP inhibition ± SD for each subgroup are represented. Differences between subgroups were assessed by a Holm-Sidak's multiple comparison test. P-value are characterized as following: ns = P>0.05; * = P≤0.05; ** = P≤0.01; *** = P≤0.001; **** = P≤0.0001

This study was financed by QUALIblood sa,
by the Walloon region (convention no. 8031)
and by Diagnostica Stago.